





Jayaseelan Boobalan¹, Thongadi Ramesh Dinesha¹, Sathasivam Sivamalar¹, Selvamurthi Gomathi¹, Aylur K. Srikrishnan¹, Shruti H. Mehta², Sunil Suhas Solomon^{1,3}, Pachamuthu Balakrishnan¹, Shanmugam Saravanan¹ ¹Y.R.Gaitonde Centre for AIDS Research & Education, Chennai, India; ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; ³Johns Hopkins University School of Medicine, Baltimore, MD, USA.


BACKGROUND

HCV is a major global health issue affecting several individuals around the world. High burden of HCV infection in people who inject drugs (PWID) in resource-limited settings (RLS) like India coupled with low access to HCV services necessitates an urgent need for evaluating less invasive DBS based HCV virologic assay for appropriately tailored therapy. Here, we present an HCV plasma viral load (PVL) and genotyping assays using dried blood spot (DBS) specimens to increase the scale-up of HCV diagnosis and monitoring.

METHODS

Thirty six paired plasma and DBS specimens [Whatman No. 903 filter paper (50µL/circle)] were collected and stored at -70°C. Two spots were excised and then lysed with 1.7mL of Abbott mLysis buffer. The lysate was then transferred and the RNA was extracted from plasma and DBS manually as per Abbott 0.5mL protocol and subjected to RT PCR and the DBS results was multiplied by dilution factor (Johansen et al., 2016). In addition, patients with $> 3 \log_{10} IU/mL DBS$ HCV RNA were further subjected to in-house one-step core/E1 RT-PCR followed by Sanger's gene sequencing. All the values were log transformed and analysis was performed on GraphPad Prism 5.0, A *p*<0.05 was considered significant.

EVALUATION OF DBS HCV RNA QUANTIFICATION AND GENOTYPING IN RESOURCE-LIMITED SETTINGS




RESULTS

- Median PVL of standard plasma HCV and DBS HCV viral load by Abbott Real Time PCR were 4.45 (IQR 2.54-5.43) and 4.18 (IQR 2.24-5.74) \log_{10} IU/mL, respectively. There was a good correlation between PVL values obtained by standard Abbott plasma and DBS assay (r = 0.97, $r^2 = 0.94$, p < 0.001) (Figure 1).
- Bland-Altman analysis has shown that, the mean difference of HCV RNA between plasma and DBS was $0.25 \log_{10} IU/mL$ and 95% limit of agreement was between -0.7321 to 1.23374 (Figure 2).
- Out of 36 samples, 21 (58%) [Median = 5.74, (IQR=4.96-5.91)] had > 3 \log_{10} IU/mL HCV RNA in DBS, of which, DBS HCV genotyping was performed for 15 participants and the remaining 6 were not able to amplify. The result shows, majority of the infection was by genotype 3b (46.6%) followed by 6xa (33%) viruses (Figure 3).

CONCLUSION

This study supports the use of DBS as an alternate to plasma specimen for the reliable quantification of HCV RNA and genotyping. Therefore, DBS could be a great interest for detecting and genotyping HCV viremic patients in resource-limited settings.







ACKNOWLEDGEMENT

We would like to thank the study participants and the staffs of YRG CARE for facilitating this study. We would also like to thank the Conference on Retroviruses and Opportunistic Infection (CROI 2018), USA for providing financial support to attend this conference.

REFERENCES

Johansen., *et al*. Plos One 11.11 (2016): e0166201

Mohamed., et al. World journal of hepatology 7.26 (2015): 2676.

Pawlotsky., et al. Hepatology 53.5 (2011): 1742-1751.

Strader., et al. Hepatology 39.4 (2004): 1147-1171.